The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

Michael Breen, CEO of GT Biopharma (GTBP), a clinical-stage biotech company, stressed that point with TheStreet Pro’s Chris ...

Fintel reports that on December 8, 2025, UBS maintained coverage of Legend Biotech Corporation - Depositary Receipt (NasdaqGS ...

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill’s hardened stance ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Two oral presentations showcase robust efficacy and durable responsesBOSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation ...

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...

From my colleague Elaine Chen: Wave Life Sciences said today that interim data show its investigational siRNA therapy cut ...

The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...

The exchange of licensing agreements was held at the Valedictory Session of the First International Science & Technology (S&T ...

The Department of Health and Human Services recently canceled $500 million in funding for vaccine research that it had previously pledged to scientists.

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...